Managing Director & Senior Partner
Daniel Gorlin joined Boston Consulting Group in 2007. He heads BCG’s health care services work in North America, leads the Health Care practice in the Great Lakes region, and runs the Great Lakes Project Leader Career Development Committee (CDC). In his client work, Daniel focuses almost exclusively on supporting health insurers, helping them build market strategies and transform their go-to-market, clinical, and digital capabilities. He is an expert on regulatory policy and has led industrywide initiatives supporting public health, equity, and social determinants of health.
Prior to joining BCG, Daniel worked as an investment analyst at Argus Partners, a health care oriented hedge fund. Prior to that, he worked in Pfizer’s International and Regulatory Affairs and Federal Governmental Affairs departments, where he helped devise international lobbying strategies on issues including patent compulsory licensing, parallel importing, and price controls.
A confluence of factors means the time-tested approaches to cost control won’t work. Insurers need to rethink how they achieve more with less while maintaining a strong customer focus and employee value proposition.
A new regulation makes detailed pricing data widely available for the first time. Providers and insurers need to prepare now for a changed competitive playing field.
Health care payers should approach this huge, high-growth market with eyes wide open.
Consolidation won’t move the needle on health care value unless the newly combined insurers use some of the savings to invest in and extend their clinical capabilities.